Get the Stockscreener App
68.27
10.83%
-8.29
After Hours:
68.48
0.21
+0.31%
Moderna Inc stock is traded at $68.27, with a volume of 9.14M.
It is down -10.83% in the last 24 hours and up +48.45% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$76.56
Open:
$76.722
24h Volume:
9.14M
Relative Volume:
1.24
Market Cap:
$27.09B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-8.3806
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
-14.41%
1M Performance:
+48.45%
6M Performance:
+99.04%
1Y Performance:
+99.15%
1-Day Range:
$67.31
$76.72
1-Week Range:
$67.31
$85.60
52-Week Range:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
68.27 | 30.38B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Form 4 Moderna Inc For: 10 July By Investing.com - Investing.com Canada
Moderna, Inc. (MRNA) grants RSUs and stock options to director Michael R. McDonnell - Stock Titan
Moderna (MRNA) files Form 3 registering director Michael R. McDonnell as insider - Stock Titan
MRNA Stock Eyes Worst Week In 11 Months After June Surge — What’s Ahead? - TradingView
Meta, Moderna among market cap stock movers on Friday By Investing.com - Investing.com India
Meta, Moderna among market cap stock movers on Friday - Investing.com
Moderna Stock Sinks 11%; Its 24 Million-Dose EU Deal Has a No-Minimum Catch - TechStock²
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Sees Significant Drop in Stock Price - GuruFocus
Biotech Stocks To Keep An Eye OnJuly 10th - MarketBeat
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout - 24/7 Wall St.
Moderna (MRNA) Sees 8.2% Decline Amid Market Fluctuations - GuruFocus
Moderna Inc Stock (MRNA) Moved Down by 8.01% on Jul 10: Facts Behind the Movement - TradingKey
Moderna secures up to 24 million RSV vaccine dose contract with Europe - Pharmaceutical Technology
QRG Capital Management Inc. Acquires New Stake in Moderna, Inc. $MRNA - MarketBeat
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? - The Motley Fool
Moderna stock stays supported as respiratory vaccine pipeline advances - AD HOC NEWS
mRNA Therapeutics Market Size, Share, Growth, 2034 - Straits Research
Why Moderna (MRNA) Stock Is Trading Up Today - Yahoo Finance
Moderna (MRNA) Stock May Sit Above Fair Value Following Pipeline Expansion - Yahoo Finance
Moderna wins EU contract for RSV vaccine supply - Reuters
Moderna Stock Drops After Morgan Stanley Sticks To Neutral Rating Despite Lifting Price Target - TIKR.com
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026 - ACCESS Newswire
Moderna schedules July 31 results call and corporate update - Stock Titan
RBC Capital Raises its Price Target on Moderna (MRNA) - Insider Monkey
Will New Board Appointment And mRNA Flu Progress Change Moderna's (MRNA) Pipeline Diversification Narrative? - Yahoo Finance
Moderna Appoints Michael McDonnell to Board of Directors - Investing News Network
Moderna (MRNA) Settles Vaccine Patent Case With $950 Million Upfront Payment - simplywall.st
MRNA Maintained by Morgan Stanley -- Price Target Raised to $39 - GuruFocus
MRNA Stock Heads to $60 as Investors Liquidate after New Moderna Board Appointment Announcement - FXLeaders
Moderna (MRNA) Welcomes Michael McDonnell to Board of Directors - GuruFocus
Why Moderna Stock Is the S&P 500’s Big Loser Today - Barron's
Moderna appoints Michael McDonnell to board; shares retreat from 52-week high - Seeking Alpha
Moderna (MRNA) Appoints Michael McDonnell to Board of Directors - GuruFocus
Moderna Inc outlines its next phase. MRNA pivots beyond Covid vaccines - AD HOC NEWS
Moderna Strengthens Board with New Financial Director - TipRanks
Moderna Inc. focuses on mRNA pipeline as investors watch Nasdaq trading - Ad-hoc-news.de
Moderna adds former Biogen CFO to board of directors By Investing.com - Investing.com Canada
Former Biogen CFO Michael McDonnell joins Moderna (NASDAQ: MRNA) board and Audit Committee - Stock Titan
Moderna, Inc. Announces Board and Committee Changes, Effective July 8, 2026 - marketscreener.com
Moderna adds former Biogen CFO Michael McDonnell to its board - Stock Titan
Bank of America Securities Reaffirms Their Sell Rating on Moderna (MRNA) - The Globe and Mail
The Moderna Omicron XBB.1.5 vaccine. Updated booster targets current variants - AD HOC NEWS
Meitav Investment House Ltd. Sells 16,067 Shares of Moderna, Inc. $MRNA - MarketBeat
Morgan Stanley Adjusts Price Target Moderna to $39 From $33, Maintains Equalweight Rating - marketscreener.com
Hsbc Holdings PLC Sells 107,077 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Stock Surges 37%, With A 6-Day Winning Spree - Trefis
Moderna Stock On Fire: Up 37% With 6-Day Winning Streak - Trefis
Form 4 Moderna Inc For: 7 July By Investing.com - Investing.com Nigeria
Moderna (MRNA) Chief Commercial Officer awarded RSUs and stock options - Stock Titan
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week - Yahoo Finance
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hoge Stephen | President |
Jun 15 '26 |
Option Exercise |
19.15 |
53,336 |
1,021,384 |
1,537,184 |
| Hoge Stephen | President |
Jun 15 '26 |
Sale |
51.37 |
53,336 |
2,739,870 |
1,483,848 |
2.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):